Michael McClellan - Teva Pharmaceutical Chief Financial Officer, Executive Vice President

TEVA Stock  ILA 5,214  30.00  0.57%   

President

Mr. Michael McClellan is Chief Financial Officer, Executive Vice President of the Company. Mr. McClellan was appointed Executive Vice President, Chief Financial Officer in November 2017. He served as Interim Group Chief Financial Officer from July 2017 to November 2017. From 2015 to November 2017, he served as Senior Vice President and CFO, Global Specialty Medicines. Prior to joining Teva, Mr. McClellan was the U.S. CFO at Sanofi, where his career spanned nearly 20 years in roles of increased responsibility in global finance and healthcare since 2017.
Age 47
Tenure 7 years
Phone(972) 3 914 8213
Webwww.tevapharm.com
McClellan received his BSBA, accounting and economics from the University of Missouri Trulaske College of Business.

Teva Pharmaceutical Management Efficiency

The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 2.26, implying the company greatly relies on financing operations through barrowing. Teva Pharmaceutical has a current ratio of 0.99, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Moshe RosenblumMelisron
59
Menahem AvivMizrahi Tefahot
64
Adi JeminiGazit Globe
45
Nissan LevyMizrahi Tefahot
56
Ittai ZeevBank Leumi Le Israel
40
Michael BarBig Shopping Centers
37
Dan YerushalmyBank Leumi Le Israel
50
Ami HayutMelisron
49
Tamar YassurBank Leumi Le Israel
51
Ran TalAzrieli Group
43
Ran OzIsrael Discount Bank
50
Hay GalisBig Shopping Centers
47
Dor LevRanAzrieli Group
42
Irit RothBank Leumi Le Israel
47
Irit SeklerPilosofAzrieli Group
50
Yoel MinzBank Leumi Le Israel
61
Ofir SaridMelisron
51
Sharon GurBank Leumi Le Israel
48
Gideon AvramiAzrieli Group
63
Ziv BironIsrael Discount Bank
46
Michal CarmiBank Leumi Le Israel
60
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel. TEVA PHARMA is traded on Tel Aviv Stock Exchange in Israel. Teva Pharmaceutical Industries (TEVA) is traded on Tel Aviv Stock Exchange in Israel and employs 34,004 people.

Management Performance

Teva Pharmaceutical Leadership Team

Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
Moshe Many, Independent Director
Richard Daniell, Executive Vice President - European Commercial
Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand
Ronit SatchiFainaro, Independent Director
Richard Lerner, Independent Director
Galia Maor, Independent Director
Janet Vergis, Independent Director
Carlo Notaristefani, CEO of Global Operations and President of Global Operations
JeanMichel Halfon, Statutory - independent director
Eli Shani, Ex Portfolio
Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations
Abbas Hussain, Independent Director
Yitzhak Peterburg, Director
Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D
Perry Nisen, Independent Director
Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director
David Stark, Executive Vice President, Chief Legal Officer
Amir Elstein, Vice Chairman of the Board
Dan Suesskind, Director
Arie Belldegrun, Independent Director
Richard Egosi, Chief Legal Officer and Group Executive VP
Andrew Weil, Chief Accounting Officer
Jean Halfon, Statutory - independent director
Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio
Robert Koremans, President CEO-Global Specialty Medicines
Gerald Lieberman, Independent Director
Roberto Mignone, Independent Director
Rosemary Crane, Independent Director
Nechemia Peres, Independent Director
Roger Abravanel, Independent Director
Eyal Desheh, CFO and Group Executive VP
Gianfranco Nazzi, Executive Vice President - International Markets Commercial
Kare Schultz, CEO Pres
Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication
Amir Weiss, VP Officer
Brendan OGrady, Executive Vice President - North America Commercial
Michael Hayden, President - Global Research and Development, Chief Scientific Officer
Gabrielle Sulzberger, Statutory Independent Director
Eric Drape, Executive Vice President - Global Operations
Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee
Eliyahu Kalif, Chief Financial Officer, Executive Vice President, Director
Kathleen Veit, Global VP
Joseph Nitzani, Independent Director
Deborah Griffin, Chief Accounting Officer
Timothy Wright, Head - Business Development, Strategy and Innovation
Sigurdur Olafsson, President and CEO - Global Generic Medicines Group
Murray Goldberg, Independent Director
Dan Propper, Independent Director
Ory Slonim, Independent Director
Michael McClellan, Chief Financial Officer, Executive Vice President
Kevin Mannix, Vice President Head of Investor Relations
Kaare Schultz, President, Chief Executive Officer, Director
Sol Barer, Independent Chairman of the Board
Eli Kalif, Chief Financial Officer, Executive Vice President, Director

Teva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharmaceutical Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Teva Stock analysis

When running Teva Pharmaceutical's price analysis, check to measure Teva Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharmaceutical is operating at the current time. Most of Teva Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Teva Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharmaceutical's price. Additionally, you may evaluate how the addition of Teva Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Commodity Directory
Find actively traded commodities issued by global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Please note, there is a significant difference between Teva Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.